Menopausal hormone therapy is the most effective treatment available for moderate to severe hot flashes and night sweats. It also carries real risks that depend on age, time since menopause, route, and personal history. This page is the evidence core — benefits, risks, and the 2026 FDA labeling context — without clinic sales language.
Key facts
- NAMS and related guidance: hormone therapy is the most effective treatment for vasomotor symptoms.1
- WHI found increased breast cancer risk with estrogen-plus-progestin in the population studied; longer follow-up refined absolute risks and age patterns.23
- Eighteen-year WHI follow-up did not show increased all-cause mortality among women who had taken hormone therapy in the trials.4
- Cardiovascular risk varies by age and years since menopause — the timing issue is not a slogan.5
- Observational data associate oral therapy with higher VTE risk than transdermal routes.6
- In 2026 the FDA removed some risks from the boxed warning while retaining important warnings in the label.78
What it is approved and evidenced to treat
Systemic menopausal hormone therapy is used for moderate to severe vasomotor symptoms, and estrogen therapy (including low-dose vaginal preparations where appropriate) addresses genitourinary syndrome of menopause. Bone protection is part of the established benefit profile in appropriate candidates.19
It is not an evidence-based general anti-aging program, a universal dementia-prevention strategy, or a requirement for every woman who is done with menstrual cycles.
Benefits versus risks (evidence map)
| Outcome | Evidence direction |
|---|---|
| Hot flashes / night sweats | Strong benefit vs nonuse; most effective available class1 |
| Genitourinary symptoms | Strong benefit; local therapy often sufficient9 |
| Fracture / bone loss | Benefit supported in trial and guideline literature3 |
| Breast cancer (E+P in WHI-like populations) | Increased risk signal; absolute risk depends on baseline and duration2 |
| Stroke / VTE | Risk elevated in important subgroups; route matters in observational data36 |
| All-cause mortality (long WHI follow-up) | No increase overall in cumulative follow-up analyses4 |
| Primary prevention of heart disease in older, late-start populations | Not supported as an indication2 |
The Women’s Health Initiative, without the mythology
The 2002 estrogen-plus-progestin report changed prescribing worldwide after increased breast cancer risk and a global risk index that halted the arm early.2 Participants were older on average than many women who start therapy for hot flashes near menopause. Later analyses showed risk and benefit varying by age, years since menopause, and outcome.35
Long-term mortality follow-up did not show a penalty in all-cause death for women randomized to hormone therapy in WHI.4 That fact is routinely over-read as “WHI was wrong about everything” and under-read as “risks were imaginary.” Neither is accurate.
Route, uterus, and duration
Women with a uterus who use systemic estrogen need endometrial protection — a foundational safety point, not a technicality. Observational evidence that oral estrogen carries more venous thrombosis risk than transdermal preparations influences real prescribing even though it is not a randomized head-to-head of every product.6
The FDA’s 2026 labeling changes removed cardiovascular disease, breast cancer, and probable dementia from the boxed warning for many products while retaining important warnings in the broader label and keeping a boxed endometrial-cancer warning on systemic estrogen-alone products.78 Communication changed; risk did not vanish.
Nonhormonal options exist
When hormones are contraindicated or declined, nonhormonal therapies have a guideline-backed role — including behavioral approaches and medications such as the NK3 receptor antagonist fezolinetant for vasomotor symptoms in trial populations.1011
Frequently asked questions
Is hormone therapy safe now that the black box changed?
“Safe” is not a yes/no label claim. The FDA changed how some risks are highlighted. Cardiovascular and breast cancer information remains in labeling, and individual risk still depends on age, timing, regimen, and history.
Should every woman start HRT at menopause?
No. The strongest case is for bothersome symptoms (and selected bone indications) in appropriate candidates, especially when started nearer to menopause. Asymptomatic prevention-only use is a different, weaker claim.
Do I need blood tests first?
Usually menopause is clinical after mid-40s with typical symptoms and cycle change. Testing has roles in early menopause, unclear presentations, or specific workups — not as a universal shopping list.
How long can I stay on it?
The old “shortest time possible” slogan was softened in 2026 labeling, but that is not a lifetime free pass. Duration is individualized and should be re-reviewed, not set-and-forgotten.
The bottom line
Hormone therapy earns its place for vasomotor and genitourinary symptoms and for bone in the right patients. WHI and its follow-up still define the risk conversation. The 2026 FDA update changed the loudest warning box, not the need for individualized medicine. If someone sells HRT as either poison or fountain of youth, they are not reading the same evidence base.